U.S. Interactive Media and Services Stock News

NasdaqGS:EQPT
NasdaqGS:EQPTTrade Distributors

Wall Street Backs EquipmentShare IPO Story With Growth And Valuation Upside

Wall Street brokerages have started coverage of EquipmentShare.com after its recent IPO, focusing on the company’s technology driven rental model. Analysts are highlighting EquipmentShare’s plans to expand its rental footprint and its capital light approach to fleet growth. The new coverage is drawing attention to the company’s goal of doubling rental locations and its position in the equipment rental industry. EquipmentShare.com, listed on NasdaqGS:EQPT, is coming onto more investors’...
NYSE:WAT
NYSE:WATLife Sciences

Waters Targets Growth With MaxPeak Columns And Four-Division Realignment

Waters Corporation (NYSE:WAT) introduced new high-sensitivity liquid chromatography columns featuring MaxPeak Premier Technology. The company completed a realignment of its operations into four focused divisions aimed at adjacent high-growth markets. Waters, a long-established player in analytical instruments and laboratory solutions, is using this product launch and business realignment to sharpen its role in analytical sciences and diagnostics. The new columns with MaxPeak Premier...
NasdaqGS:LBTY.A
NasdaqGS:LBTY.ATelecom

Liberty Global (LBTY.A) Quarterly Loss Narrows Yet LTM US$1.9b Loss Reinforces Bearish Narratives

Liberty Global (LBTY.A) has reported another tough set of numbers for FY 2025, with Q3 revenue of US$1,207.1 million and a basic EPS loss of US$0.27, alongside trailing 12 month revenue of US$4.8 billion and a basic EPS loss of US$5.47. Over recent periods, the company has seen revenue move from US$1,069.5 million in Q3 2024 to US$1,207.1 million in Q3 2025, while EPS has shifted from a loss of US$4.0 in Q3 2024 to a loss of US$0.27 in Q3 2025. Overall, the latest figures keep the spotlight...
NYSE:DRD
NYSE:DRDMetals and Mining

DRDGOLD (NYSE:DRD) Margin Surge To 28.5% Tests Bearish Profitability Narratives

DRDGOLD (NYSE:DRD) has put up another firm set of numbers for H1 2026, with H2 2025 revenue at R4.1b and basic EPS of R14.76 sitting on top of R1.3b in net income, while the trailing twelve month line shows revenue of R7.9b and basic EPS of R26.01 backed by R2.2b in net income. The company has seen revenue move from R3.3b in H2 2024 to R3.8b in H1 2025 and then R4.1b in H2 2025, alongside basic EPS stepping from R8.58 to R11.26 and then R14.76. This progression sets a clear earnings rhythm...
NasdaqGS:DOX
NasdaqGS:DOXIT

Amdocs (DOX) Margin Improvement To 12.5% Tests Longstanding Earnings Skepticism

Amdocs (DOX) has opened Q1 2026 with revenue of US$1.2 billion and basic EPS of US$1.46, setting the tone for investors focused on how profit is tracking against prior quarters. The company has seen quarterly revenue hold around the US$1.1 billion mark over the past year, from US$1.11 billion in Q1 2025 to US$1.16 billion in Q1 2026. Over the same period, basic EPS moved from US$1.34 to US$1.46, and trailing twelve month EPS sits at US$5.19. With net profit margins having improved over the...
NYSE:TOL
NYSE:TOLConsumer Durables

Toll Brothers (TOL) Margin Compression Challenges Bullish Luxury Housing Narratives

Toll Brothers (TOL) opened its 2026 fiscal year with Q1 revenue of US$2.1b and basic EPS of US$2.20, setting the tone for how its upscale housing demand is feeding through to the bottom line. The company has seen quarterly revenue move from US$1,859.1m and EPS of US$1.76 in Q1 2025 to US$2,145.6m and EPS of US$2.20 in Q1 2026. Trailing 12 month EPS sits at US$14.12 on revenue of US$11.3b, giving investors a clear view of scale. With a trailing net margin of 12.3% versus 14.0% last year, the...
OTCPK:ELTP
OTCPK:ELTPPharmaceuticals

Elite Pharmaceuticals (OTCPK:ELTP) Profit Turnaround Challenges Bearish Earnings Quality Narratives

Elite Pharmaceuticals (ELTP) just posted its Q3 2026 numbers, with revenue of US$31.6 million, basic EPS of US$0.017, and net income of US$18.6 million, while on a trailing twelve month basis revenue sits at US$140.1 million and EPS at US$0.040. Over the past few quarters, the company has seen revenue move between US$14.4 million and US$40.2 million per quarter, with basic EPS ranging from a loss of US$0.010 to a profit of US$0.018, and trailing twelve month EPS shifting from a loss of...
NasdaqGS:CZR
NasdaqGS:CZRHospitality

Caesars Entertainment (CZR) EPS Swing To Q4 Loss Tests Bullish Recovery Narrative

Caesars Entertainment (CZR) closed out FY 2025 with fourth quarter revenue of US$2.9 billion, a basic EPS loss of US$1.23 and a net income loss of US$250 million, compared with revenue of US$2.8 billion, basic EPS of US$0.05 and net income of US$11 million in the same quarter a year earlier. Over the past year, the company has seen quarterly revenue range from US$2.8 billion to US$2.9 billion, while basic EPS moved from a US$0.27 loss in Q3 2025 to a US$1.23 loss in Q4 2025. Trailing twelve...
NasdaqGS:MKSI
NasdaqGS:MKSISemiconductor

MKS Instruments (MKSI) Earnings Surge And Margin Expansion Test Bullish AI‑Driven Narratives

MKS (MKSI) has wrapped up FY 2025 with Q4 revenue of US$1.0b and basic EPS of US$1.60, alongside trailing twelve month revenue of US$3.9b and EPS of US$4.38 that sit against a 55.3% earnings lift over the past year. The company has seen quarterly revenue move from US$934m in Q4 2024 to US$1.0b in Q4 2025, while basic EPS shifted from US$1.35 to US$1.60 over the same period. Analysts are forecasting 27.9% annual earnings growth and higher net profit margins, keeping investor attention firmly...
NYSE:MNR
NYSE:MNROil and Gas

Mach Natural Resources Balances Integration Issues With Higher Cash Distributions

Mach Natural Resources (NYSE:MNR) is working through integration challenges tied to newly acquired oil assets in the Central Basin Platform. At the same time, the company has announced an increase in its quarterly cash distribution to unitholders. The combination of operational complexity and higher cash returns has drawn fresh attention from investors and analysts. Mach Natural Resources comes into this news with a recent unit price of $13.31 and a mixed return profile. The units are up...
NasdaqGM:NAMS
NasdaqGM:NAMSBiotechs

NewAmsterdam Expands Obicetrapib Trials Into Diabetes And Alzheimer’s As Losses Mount

NewAmsterdam Pharma has begun late stage RUBENS Phase 3 trials of obicetrapib in patients with Type 2 diabetes and metabolic syndrome. The company also plans to launch a new trial of obicetrapib in early Alzheimer's disease. These programs expand obicetrapib's potential use into major cardiometabolic and neurological conditions. For investors watching NasdaqGM:NAMS, these trial moves come as the stock trades at $35.24 and has returned 75.8% over the past year and 237.2% over the past five...
NYSE:BTGO
NYSE:BTGOCapital Markets

Is There Now An Opportunity In Bitgo Holdings (BTGO) After 41% Year To Date Share Price Fall

If you are trying to figure out whether Bitgo Holdings at around US$10.87 is a bargain or a value trap, starting with a clear view of what the current price reflects can help you frame the opportunity and the risks. The stock has seen a 1.4% decline over the last 7 days and a 41.2% decline year to date, which can change how the market views its growth potential and risk profile. Recent coverage around Bitgo Holdings has focused on its role in digital asset custody and broader crypto market...
NasdaqGM:CAN
NasdaqGM:CANTech

A Look At Canaan (NasdaqGM:CAN) Valuation After Earnings, 2026 Guidance And January Bitcoin Production Update

Why Canaan’s latest numbers matter for shareholders Canaan (NasdaqGM:CAN) just released fourth quarter and full year 2025 results, fresh earnings guidance for the first quarter of 2026, and January Bitcoin production data, giving investors several new reference points to assess the stock. For the fourth quarter ended December 31, 2025, Canaan reported revenue of US$196.27 million, compared with US$88.77 million a year earlier. The company recorded a net loss of US$85.04 million for the...
NYSE:CRL
NYSE:CRLLife Sciences

New Charles River Leaders May Shape Valuation, Debt And Governance Outlook

Charles River Laboratories International (NYSE:CRL) has appointed Glenn G. Coleman as Chief Financial Officer. The company has also named Kerry Dailey as Chief Legal Officer, expanding its senior leadership bench. These leadership changes are aimed at reinforcing financial oversight, legal governance, and corporate compliance. Charles River Laboratories operates as a key partner for pharmaceutical and biotech companies, supporting drug discovery, preclinical research, and related services...
NasdaqGS:BMRC
NasdaqGS:BMRCBanks

3 Stocks That May Be Trading Below Estimated Fair Value

As February begins, major U.S. stock indexes have shown strong performance, with the Dow Jones Industrial Average climbing 515 points and the S&P 500 nearing a record high. Amid this positive momentum, investors may find opportunities in stocks that appear to be trading below their estimated fair value, potentially offering attractive entry points in a market characterized by robust gains and evolving economic conditions.
OTCPK:CVSI
OTCPK:CVSIPersonal Products

Promising Penny Stocks To Consider In February 2026

As February 2026 kicks off, major stock indexes in the United States have shown impressive gains, with the Dow Jones Industrial Average climbing by 515 points and the S&P 500 nearing a record high. In such a buoyant market atmosphere, investors often look beyond established giants to explore opportunities in lesser-known areas like penny stocks. Although 'penny stock' is an older term, it still denotes smaller or newer companies that can offer significant potential when backed by strong...
NYSE:DTE
NYSE:DTEIntegrated Utilities

DTE Energy (DTE) Margin Compression Tests Long Term Earnings Resilience Narrative

DTE Energy FY 2025 Earnings Snapshot DTE Energy (DTE) has wrapped up FY 2025 with fourth quarter revenue of US$4.4 billion and basic EPS of US$1.80, setting the tone for how investors assess the full year. The company has seen quarterly revenue range from US$3.4 billion to US$4.4 billion over 2025, while basic EPS moved between US$1.10 and US$2.14. This gives a clear view of how the top line and per share earnings have tracked across the year. With a trailing net profit margin of 9.2% versus...
NasdaqGS:BHF
NasdaqGS:BHFInsurance

Brighthouse Deal Wins Shareholder Backing But Valuation Signals Big Discount

Brighthouse Financial (NasdaqGS:BHF) stockholders have approved the company’s acquisition by Aquarian Holdings. The vote took place at a special meeting of shareholders, clearing a key condition under the merger agreement. This approval sets the stage for Brighthouse Financial to transition to new ownership, subject to remaining closing conditions and regulatory clearances. Brighthouse Financial focuses on life insurance and annuity products, areas that continue to draw attention from...
NasdaqCM:CZFS
NasdaqCM:CZFSBanks

Undervalued Small Caps With Insider Activity To Watch In February 2026

As February 2026 begins, U.S. markets have experienced a robust start with key indices like the Dow Jones Industrial Average and S&P 500 posting significant gains, reflecting renewed investor optimism amid positive economic indicators such as the expansion in manufacturing activity. In this dynamic environment, identifying small-cap stocks with potential for growth can be particularly rewarding; factors such as insider activity may offer additional insights into their valuation and future...
NasdaqGS:ERII
NasdaqGS:ERIIMachinery

Three Stocks That May Be Trading Below Estimated Value In February 2026

As February 2026 unfolds, the U.S. stock market has kicked off the month on a high note, with major indices like the Dow Jones Industrial Average and S&P 500 experiencing significant gains. Amidst this optimistic start, investors are keen to identify stocks that may be trading below their estimated value, particularly as economic indicators suggest potential shifts in trade dynamics and manufacturing activity. In such an environment, discerning investors often look for stocks with strong...
NasdaqGM:HROW
NasdaqGM:HROWPharmaceuticals

February 2026 Insider Favorites For Growth Stocks

As February 2026 begins, U.S. stock markets are experiencing a robust start with major indices like the Dow Jones and S&P 500 posting significant gains, despite recent economic uncertainties such as government shutdowns and trade negotiations. In this invigorated market environment, investors often look for growth companies with high insider ownership as these stocks can indicate confidence from those closest to the company's operations and strategy.